Descovy: New Indication for HIV Pre-exposure Prophylaxis
Jace Swingle, Madison Grilliot
Abstract
​Human Immunodeficiency Virus (HIV) is a viral infection spread by contact with bodily fluids. If untreated, it results in severe immunodeficiency and ultimately death. In the 1990’s, treatments to enhance the duration and quality of life were developed, and more recently, treatments have been designed to help prevent HIV infection. Currently, there is no cure for HIV infection; therefore, prevention is key to maintaining a healthy lifestyle in high risk patients. This article features a new indication for Descovy (emtricitabine and tenofovir alafenamide), which was approved by the FDA for HIV pre-exposure prophylaxis (PrEP).
Full Text
Descovy_for_PrEP.pdf
File Size: 299 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH